Literature DB >> 11520987

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

J Lewis1, D W Dickson, W L Lin, L Chisholm, A Corral, G Jones, S H Yen, N Sahara, L Skipper, D Yager, C Eckman, J Hardy, M Hutton, E McGowan.   

Abstract

JNPL3 transgenic mice expressing a mutant tau protein, which develop neurofibrillary tangles and progressive motor disturbance, were crossed with Tg2576 transgenic mice expressing mutant beta-amyloid precursor protein (APP), thus modulating the APP-Abeta (beta-amyloid peptide) environment. The resulting double mutant (tau/APP) progeny and the Tg2576 parental strain developed Abeta deposits at the same age; however, relative to JNPL3 mice, the double mutants exhibited neurofibrillary tangle pathology that was substantially enhanced in the limbic system and olfactory cortex. These results indicate that either APP or Abeta influences the formation of neurofibrillary tangles. The interaction between Abeta and tau pathologies in these mice supports the hypothesis that a similar interaction occurs in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520987     DOI: 10.1126/science.1058189

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  449 in total

1.  Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery.

Authors:  John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

Review 2.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.

Authors:  Dennis J Selkoe
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 3.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

Review 4.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

5.  Increased hippocampal neurogenesis in Alzheimer's disease.

Authors:  Kunlin Jin; Alyson L Peel; Xiao Ou Mao; Lin Xie; Barbara A Cottrell; David C Henshall; David A Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-05       Impact factor: 11.205

6.  Amyloid peptide toxicity and microtubule-stabilizing drugs.

Authors:  Mary L Michaelis; Yingxue Chen; Sarah Hill; Emily Reiff; Gunda Georg; Antonie Rice; Kenneth Audus
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 7.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

Review 8.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

Review 9.  The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease.

Authors:  Ekaterina Rogaeva
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

10.  The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons.

Authors:  Christina R Muratore; Heather C Rice; Priya Srikanth; Dana G Callahan; Taehwan Shin; Lawrence N P Benjamin; Dominic M Walsh; Dennis J Selkoe; Tracy L Young-Pearse
Journal:  Hum Mol Genet       Date:  2014-02-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.